Neumentum, Inc. is a privately held pain and neurology specialty pharmaceutical company that is developing novel, non-opioid pain therapeutics. The Company’s lead product candidate, NTM-001- Toradol PMB (Pre-Mixed Bag Ketorolac for Continuous Infusion) is an alcohol-free injectable analgesic that can be continuously infused over 24 hours for postoperative pain. NTM-001-Toradol PMB is a Phase 3–ready asset that we believe may be approved and launched within 24 months. Neumentum currently has worldwide rights to five product candidates that have the potential to drive both significant commercial success and, more importantly, may, once approved, offer a meaningful improvement to patients suffering from pain. All of these product candidates represent the opportunity for potentially efficacious, safer alternatives to opioid analgesics that we believe could address unmet needs for providers, payers, and patients.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):